Expanding Global Reach of Novel Cannabinoids and Terpenes: Fostering International Trade

The global cannabis industry is witnessing a significant evolution with the extraction and identification of new cannabinoids and terpenes beyond the traditional THC and CBD. Compounds such as Cannabigerol (CBG), Cannabichromene (CBC), Tetrahydrocannabivarin (THCV), Cannabinol (CBN), Delta-8 THCp, Delta-9 THCp, Delta-9 THCPo, HHCp, HHCPo, THCa Isolate, THCb, and THCh, along with a variety of terpenes, have emerged, each offering unique potential medical benefits. As leaders in this industry, OilWell CBD is committed to providing these groundbreaking compounds to our international customers.

Japan, known for its strict regulations requiring less than 0.03% THC in imported products, has shown substantial interest in these novel cannabinoids, many of which have minimal or no THC content. Our dedicated team works tirelessly to satisfy this market’s demand while navigating its stringent import regulations.

However, the influence of these new cannabinoids extends far beyond Japan. In Europe, where natural health remedies are favored, there is growing interest in non-psychoactive cannabinoids and terpenes. Progressive nations like the Netherlands, Germany, and Spain are championing this trend.

Across the Americas, the U.S. and Canada are significant markets for these novel compounds, while in South America, countries including Argentina and Colombia are exploring their medical and commercial potential. Australia’s thriving cannabis market is another landscape offering vast opportunities for these products.

African nations like Lesotho and South Africa, using their advantageous climates, have entered the industry, cultivating cannabis for cannabinoid extraction and adding another dimension to the global cannabis trade.

In Europe, the preference for natural remedies is driving demand for these cannabinoids. Progressive cannabis laws in countries like the Netherlands, Germany, and Spain have facilitated their adoption.

Across the Americas, Australia, and Africa, the potential of these novel cannabinoids is being realized due to the evolving legal landscape, rising health awareness, and a burgeoning cannabis industry. The continued global interest in these cannabinoids underscores their potential therapeutic significance and their potential role in reshaping the cannabis industry worldwide.

• Cannabigerol (CBG): Often referred to as the ‘mother of all cannabinoids’, CBG is a non-psychoactive cannabinoid that could potentially aid with inflammation and pain relief. These qualities make it a promising candidate for therapeutic use in countries where cannabis is legalized for medical purposes.
• Cannabichromene (CBC): Another non-psychoactive cannabinoid, CBC, has shown potential in treating depression and anxiety, garnering attention in countries where mental health awareness is rising.
• Tetrahydrocannabivarin (THCV): Noted for its potential in managing diabetes and panic disorders, THCV offers a unique contribution to the medical cannabis market, particularly in regions where these conditions are prevalent.
• Cannabinol (CBN): Known for its potential sedative effects, CBN might be a natural remedy for those struggling with sleep disorders like insomnia. Countries with a high incidence of sleep-related disorders are therefore increasingly interested in this cannabinoid.
• Delta-8 THCp and Delta-9 THCp: These cannabinoids are gaining interest for their potential analgesic (pain-relieving) and anti-inflammatory properties. They could serve as valuable alternatives to traditional pain management therapies.
• Delta-9 THCPo, HHCp, HHCPo: Emerging research suggests these compounds might offer significant medicinal properties, making them of interest to countries that are actively developing their medicinal cannabis markets.
• THCa Isolate: This non-psychoactive cannabinoid in its isolated form has shown promise in relieving inflammation and neurological disorders. Countries with a focus on neurodegenerative conditions may find THCa Isolate particularly valuable.
• THCb and THCh: These are relatively unexplored cannabinoids but could potentially offer unique therapeutic properties. Their discovery has fueled research interest worldwide.

These cannabinoids’ surge in popularity in various countries is largely due to evolving cannabis regulations, growing awareness about potential medical benefits, and a shift towards natural health remedies. For instance, in countries like Japan, where THC levels in imported products must be below 0.03%, cannabinoids like CBG, CBC, and CBN are gaining popularity due to their non-psychoactive nature.

At OilWell CBD, our focus remains on meeting our international customers’ needs. We offer a diverse array of products, including those with varying levels of THC, and even THC-free products, to cater to different regional regulations and customer preferences.

Our innovative selection includes Delta-8 THCp, Delta-9 THCp, and Delta-9 THCPo, all potential game-changers in pain management and therapeutic treatments. HHCp and HHCPo are also on our roster, demonstrating promising medicinal properties. THCa Isolate, THCb, and THCh are explored for their potential benefits in inflammation, pain relief, and neurological disorders. We also offer a range of terpenes, aromatic compounds that can enhance the benefits of cannabinoids and contribute to the ‘entourage effect’.

OilWell CBD is excited to lead the global trade of these novel cannabinoids and terpenes. We adhere to strict quality control measures to ensure our products comply with local regulations and meet the highest safety standards. As we continue to expand our global footprint, we eagerly anticipate creating new partnerships and sharing the benefits of these ground-breaking compounds. We extend our gratitude to our international partners and customers for their trust and shared passion for exploring these promising new landscapes together.